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Abstract 
Leishmaniasis is an infectious disease that is endemic in 88 countries. Most of the patients after recovery from 
the infection develop a long-lived natural immunity against re-infection. Reactivation of leishmaniasis 
subsequent to suppression of the immune system due to HIV infection or administration of systemic 
immunosuppressive drugs, underscores the importance of developing new drugs and effective vaccine. Despite 
the many efforts that have been done, there is still no effective vaccine. Up to now, many candidate vaccines 
from three generations of the vaccine, including Live/killed vaccines, subunit vaccines, and DNA vaccines 
have been developed and studied. However the sophisticated vaccines, such as prime-boost DNA vaccines are 
introduced, the best results are obtained from live vaccines. As safety is the most important obstacle to the use 
of live vaccines, many different approaches have been used to enhance the safety of live vaccine candidates. In 
this short review, these approaches are summarized. 
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Leishmaniasis is a parasitic disease caused by an 
obligate protozoan transmitted to hosts such as 
human, rodents, and canids through the bite of 
infected female sand fly. More than 50 Leishmania 
species have been identified, and over 20 leishmania 
species have been described that are pathogenic for 
human
1
. Leishmaniasis is endemic in 88 countries. 
Currently, 350 million people are at the risk of this 
disease, and 1.5 million new cases are infected 
annually. Leishmaniasis, schistosomiasis, and 
hookworm infection impose the highest disease 
burden among the tropical diseases, and World 
Health Organization considered them as neglected 
diseases
2–4
. The spectrum of clinical manifestations of 
the disease is wide, ranging from simple cutaneous 
leishmaniasis (CL) and mucosal/mucocutaneous 
infection to serious visceral leishmaniasis
5,6
. CL is the 
most common form of leishmaniasis, with lowest 
mortality rate among all clinical forms, and is 
responsible for 50–75% of all new cases
2
. Leishmania 
species that causes cutaneous form of the disease are 
Leishmania major, L. tropica, L. aethiopica, L. 
mexicana, L. braziliensis, L. guyanensis, L. 
panamensis, L. peruviana, and L. amazonensis
7
. 
Nowadays, treatment of all clinical forms of 
leishmaniasis is highly dependent on 
chemotherapeutic agents, including Pentavalent 
Antimonials and Amphotericin B
8
. This therapy is 
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usually effective; however, factors such as side 
effects, duration of treatment, and high costs are the 
concerns that make the therapy challeng. 
Additionally, reports on the emergence of drug 
resistant strains further highlights the need for an 
effective vaccine
9
. Reactivation of asymptomatic 
leishmania infections in immunocompromised 
patients, especially in HIV infected patients, 
accelerates the progression of the disease, providing 




A good understanding of immunity, which is 
generated against Leishmania, is a key element to 
develop an efficient vaccine. Resistance to infection 
depends on cell-mediated immune responses. 
Previous studies on C57BL/6 mice revealed that a 
high level production of interferon gamma via T 
helper1 (Th1) cells promotes macrophages to deviate 
to M1 classical phenotype, which can promote 
phagocytosis, and then kill the parasites effectively 
using NO and other free radicals
11,12
. The generation 
of immunological memory is a fundamental 
requirement of effective immunity and vaccination. 
Results of studies showed that long-lasting immunity 
against leishmaniasis requires the involvement of 
both a Th1-mediated immune response and 







Strategies to develop vaccine against Leishmania 
major 
History of vaccination against leishmaniasis goes 
back to ancient times, however, no effective vaccine 
has been introduced
15
. The finding that most 
individuals who have been infected naturally, and 
then recovered, develop resistance to later re-
infection due to long-lived immunity, supports the 
notion of the possibility of developing an effective 
vaccine
16,17
. Inoculation of the live L.major in a non-
visible part of the skin induces a usually benign 
infection with spontaneous healing after 6–9 months. 
This vaccine is called leishmanization and was the 
first strategy to develop immunity against 
leishmaniasis. During the 1980s more than two 
million people in Iran were immunized by 
leishmanization; this program reduced the incidence 
of the disease
18
. As mentioned, CL caused by 
leishmanization, usually produces a self-healing 
lesion. Although rarely, in some cases, the sore 
remained for a long time and increased the risk of 
disseminated leishmaniasis in immunocompromised 
individuals
19,20
. In addition, due to the increase in the 
prevalence of HIV infection and growth in the use of 
immunosuppressive drugs, the risk attributed to 
leishmanization is increased. Nowadays, 
leishmanization is no longer used because of serious 
concerns about its safety and standardization
20
. 
Although, still is used in Uzbekistan
21,22
.  
Besides leishmanization, several approaches have been 
used to develop a safe and effective vaccine against 
leishmaniasis, including killed vaccines, subunit 
vaccines, and DNA vaccines
23–25
. Despite the great 
efforts have been done to develop a vaccine by using 
these approaches, none of them reached the clinical 
trials. In recent years, the use of live leishmania has 
been suggested again. Live vaccines are sufficiently 
potent to stimulate proper immune responses. 
Additionally, the results of previous studies showed 
that to sustain immunological memory, persistence of 
a small number of live parasites is essential 
(concomitant immunity)
13,14,26
. Therefore, live vaccine 
can be considered as the gold standard for protection 
against leishmaniasis. The problem of non-healing 
lesions that appeared in some cases followed by 
leishmanization is the main obstacle in the way of 
using live parasite as a vaccine. To conquer this 
problem, different solutions have been employed such 
as using live attenuated organisms, non-pathogen 
organism, and  live pathogenic Leishmania with an 
appropriate adjuvant to reduce the pathological effects 
of live vaccines
27–30
 (Figure 1).  
The main goal in live vaccine research is the 
prevention of lesion formation, and at the same time 
the development of long lasting immunity. There is 
evidence from a preliminary clinical study in 
Uzbekistan that killed promastigotes delivered with 
live vaccine reduced the size and duration of active 
lesions. Another approach to reach the goal is 
inoculation of virulent L. major with an appropriate 
adjuvant in order to induce an immune response 
similar to natural infection, to make the response  
more rapid and robust, so as to promote earlier control 
of parasite growth and healing of cutaneous 
lesions. Mendez S. et al. successfully developed a 
leishmanization protocol by mixing live L. major with 
CpG-containing immunostimulatory 
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oligodeoxynucleotides to minimizes pathology while 




Another method which is used to reduce pathological 
effects of L. major inoculation is attenuation of 
virulence. Several procedures have been used to 
develop a live attenuated Leishmania vaccine, 
including chemical mutagenesis, serial in 
vitro cultures, temperature sensitivity, and 
irradiation. Datta S. et al. used Ultraviolet-A 
radiation and psoralen compound for production of 
an attenuated viable Leishmania called killed but 
metabolically active Leishmania strain (KBMA). 
Results showed that KBMA leishmania induced 
strong Th1 responses in susceptible mice and could 
be considered as candidate vaccine
32
.  
Targeted gene disruption of both alleles have been 
used previously to produce live attenuated L. major. 
The first L. major modified gene was a dihydrofolate 
reductase thymidylate synthase gene, gave 
disappointing results during further studies in 
monkeys
33
. Although, safety concerns regarding 
conversion back to virulence form make them 
questionable for human use. Another approach is the 
addition of the suicide cassettes to the genome of 
parasites that could provide suitable candidates for 
leishmanization, to guarantee  an effective treatment 
of non-resolving lesions. The suicide cassette is 
translated in response to external stimuli, and kills the 
parasite. An example of this method is the  gene 
modified L. major, which is sensitive to 5-
fluorocytosine or Ganciclovir
34
. Despite good results 
in animal studies, no such formulation has reached 
even in pre-clinical stage as yet.  
In spite of the investigations aimed at artificially 
attenuated wild Leishmania spp., some researchers 
focused on live natural non-
pathogenic Leishmania strains. Breton M et al. 
recently introduced lizard protozoan parasite L. 
tarentolae, that is nonpathogenic to human, as a 
vaccine candidate against leishmaniasis
35
. It should be 
highlighted that L. tarentolae infection is cleared 
rapidly, but cannot induce the "concomitant 
immunity". Recently, a group of researchers have 
begun efforts to use L. tarentolae in a novel live-
vaccination strategy. In this regard, Zahedifard F et al. 
immunized BALB/c mice with a live recombinant L. 
tarentolae expressing sand fly saliva antigens together 
with two types of cysteine proteinases from L. major. 
The results of this study showed that vaccination 
induced a strong parasites specific TH1 response and 
conferred protection against L. major infection
36
. It 
should be considered that L. tarentolae disappears 
quickly by macrophages
35
, therefore, use of agents that 
increase the asymptomatic persistent infections of this 
parasites, may promote the immunological memory 
 
 
Figure 1. Classification of strategies used in researches to develop Leishmania. major live vaccines. 
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formation. Additionally, utilization of other 
leishmania spp. with the lower pathogenicity and also 
higher persistency in macrophages, may increase the 
efficiency of vaccination. 
Conclusion 
Over the years, great efforts have been done, and 
many advances have been achieved, nonetheless, 
there is no vaccine to insure sufficient level of 
protection against leishmania infection yet. However, 
properties of a successful vaccine against CL are 
known. Effective CL vaccine should primes a robust 
parasite-specific TH1-cell responses to induce an 
appropriate phagocytic function, as well as, induction 
of adequate specific regulatory response to support 
long-lasting memory T cell formation, thise property  
have not been included in the attempts to produce 
leishmaniasis vaccine before. In addition, a 
successful vaccine should be safe. It is important to 
consider that live attenuated parasites may return to 
virulence form; hence, non-pathogenic leishmania-
based vaccines are powerful tools to conquer 
Leishmania infection. Moreover, main problems 
associated with the production of live vaccines, 
including standards and quality control - which 
existed from the beginning - must be considered too. 
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